Proteasome Inhibitors as Immunosuppressants: Biological Rationale and Clinical Experience

Eva Moran, Federico Carbone, Valeria Augusti, Franco Patrone, Alberto Ballestrero, Alessio Nencioni

Research output: Contribution to journalArticle

Abstract

Accumulating evidence supports the potential of proteasome inhibitors as immunosuppressants. Proteasome inhibitors interfere with antigen processing and presentation, as well as with the signaling cascades involved in immune cell function and survival. Both myeloma and healthy plasma cells appear to be highly susceptible to proteasome inhibitors due to impaired proteasomal activity in both cell types. As a consequence, these agents can be used to reduce antibody production and thus prevent antibody-induced tissue damage. Several clinical studies have explored the potential of bortezomib, a peptide boronate proteasome inhibitor, for treating immune disorders, such as antibody-mediated organ rejection and graft-versus-host disease (GVHD), with encouraging results. Here, we discuss the biological rationale for the use of proteasome inhibitors as immunosuppressive agents and review the clinical experience with bortezomib in immune-mediated diseases.

Original languageEnglish
Pages (from-to)270-276
Number of pages7
JournalSeminars in Hematology
Volume49
Issue number3
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Proteasome Inhibitors
Immunosuppressive Agents
Immune System Diseases
Antigen Presentation
Antibodies
Graft vs Host Disease
Multiple Myeloma
Antibody Formation
Cell Survival
Transplants
Peptides

ASJC Scopus subject areas

  • Hematology

Cite this

Proteasome Inhibitors as Immunosuppressants : Biological Rationale and Clinical Experience. / Moran, Eva; Carbone, Federico; Augusti, Valeria; Patrone, Franco; Ballestrero, Alberto; Nencioni, Alessio.

In: Seminars in Hematology, Vol. 49, No. 3, 07.2012, p. 270-276.

Research output: Contribution to journalArticle

Moran, Eva ; Carbone, Federico ; Augusti, Valeria ; Patrone, Franco ; Ballestrero, Alberto ; Nencioni, Alessio. / Proteasome Inhibitors as Immunosuppressants : Biological Rationale and Clinical Experience. In: Seminars in Hematology. 2012 ; Vol. 49, No. 3. pp. 270-276.
@article{287e47e1a6a748e9b899ee08f9beacf7,
title = "Proteasome Inhibitors as Immunosuppressants: Biological Rationale and Clinical Experience",
abstract = "Accumulating evidence supports the potential of proteasome inhibitors as immunosuppressants. Proteasome inhibitors interfere with antigen processing and presentation, as well as with the signaling cascades involved in immune cell function and survival. Both myeloma and healthy plasma cells appear to be highly susceptible to proteasome inhibitors due to impaired proteasomal activity in both cell types. As a consequence, these agents can be used to reduce antibody production and thus prevent antibody-induced tissue damage. Several clinical studies have explored the potential of bortezomib, a peptide boronate proteasome inhibitor, for treating immune disorders, such as antibody-mediated organ rejection and graft-versus-host disease (GVHD), with encouraging results. Here, we discuss the biological rationale for the use of proteasome inhibitors as immunosuppressive agents and review the clinical experience with bortezomib in immune-mediated diseases.",
author = "Eva Moran and Federico Carbone and Valeria Augusti and Franco Patrone and Alberto Ballestrero and Alessio Nencioni",
year = "2012",
month = "7",
doi = "10.1053/j.seminhematol.2012.04.004",
language = "English",
volume = "49",
pages = "270--276",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Proteasome Inhibitors as Immunosuppressants

T2 - Biological Rationale and Clinical Experience

AU - Moran, Eva

AU - Carbone, Federico

AU - Augusti, Valeria

AU - Patrone, Franco

AU - Ballestrero, Alberto

AU - Nencioni, Alessio

PY - 2012/7

Y1 - 2012/7

N2 - Accumulating evidence supports the potential of proteasome inhibitors as immunosuppressants. Proteasome inhibitors interfere with antigen processing and presentation, as well as with the signaling cascades involved in immune cell function and survival. Both myeloma and healthy plasma cells appear to be highly susceptible to proteasome inhibitors due to impaired proteasomal activity in both cell types. As a consequence, these agents can be used to reduce antibody production and thus prevent antibody-induced tissue damage. Several clinical studies have explored the potential of bortezomib, a peptide boronate proteasome inhibitor, for treating immune disorders, such as antibody-mediated organ rejection and graft-versus-host disease (GVHD), with encouraging results. Here, we discuss the biological rationale for the use of proteasome inhibitors as immunosuppressive agents and review the clinical experience with bortezomib in immune-mediated diseases.

AB - Accumulating evidence supports the potential of proteasome inhibitors as immunosuppressants. Proteasome inhibitors interfere with antigen processing and presentation, as well as with the signaling cascades involved in immune cell function and survival. Both myeloma and healthy plasma cells appear to be highly susceptible to proteasome inhibitors due to impaired proteasomal activity in both cell types. As a consequence, these agents can be used to reduce antibody production and thus prevent antibody-induced tissue damage. Several clinical studies have explored the potential of bortezomib, a peptide boronate proteasome inhibitor, for treating immune disorders, such as antibody-mediated organ rejection and graft-versus-host disease (GVHD), with encouraging results. Here, we discuss the biological rationale for the use of proteasome inhibitors as immunosuppressive agents and review the clinical experience with bortezomib in immune-mediated diseases.

UR - http://www.scopus.com/inward/record.url?scp=84862653224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862653224&partnerID=8YFLogxK

U2 - 10.1053/j.seminhematol.2012.04.004

DO - 10.1053/j.seminhematol.2012.04.004

M3 - Article

C2 - 22726551

AN - SCOPUS:84862653224

VL - 49

SP - 270

EP - 276

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 3

ER -